Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate

Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate is an orally active porphyrin inducer and ferrochelatase inhibitor. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can induce small bile duct obstruction in mice, resulting in blocked bile excretion and causing cholestasis. Long-term use of Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can cause damage to bile duct epithelial cells, inflammatory responses, and liver fibrosis. Diethyl 2,4,6-trimethyl-1,4-dihydropyridine-3,5-dicarboxylate can be used to simulate the pathological features of cholestatic liver diseases such as sclerosing cholangitis (PSC) [1][2][3][4][5][6].

Product Specifications

CAS Number

[632-93-9]

Product Name Alternative

BYK61359

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ferrochelatase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/diethyl-2-4-6-trimethyl-1-4-dihydropyridine-3-5-dicarboxylate.html

Purity

99.83

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC1C(C(OCC)=O)=C(NC(C)=C1C(OCC)=O)C

Molecular Formula

C14H21NO4

Molecular Weight

267.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Oliva J, et al. Fat10 is an epigenetic marker for liver preneoplasia in a drug-primed mouse model of tumorigenesis. Exp Mol Pathol. 2008 Apr;84 (2) :102-12. |[2]Mostert V, et al. Serum iron increases with acute induction of hepatic heme oxygenase-1 in mice. Drug Metab Rev. 2007;39 (2-3) :619-26. |[3]Laure-Alix Clerbaux, et al. Relevance of the CDE and DDC Mouse Models to Study Ductular Reaction in Chronic Human Liver Diseases. 20 December 2017|[4]Wu B, et al. A spatiotemporal atlas of cholestatic injury and repair in mice. Nat Genet. 2024 May;56 (5) :938-952. |[5]Zhang J, et al. P4HA2 induces hepatic ductular reaction and biliary fibrosis in chronic cholestatic liver diseases. Hepatology. 2023 Jul 1;78 (1) :10-25.|[6]Kudira R, et al. Bile acids engage the SIPR-STAT3 signaling axis to modulate regulatory T cell responses in fibrosing cholangiopathies. J Hepatol. 2025 Nov;83 (5) :1128-1141